Apellis Pharmaceuticals Inc.

45.57+0.8100+1.81%Vol 803.79K1Y Perf 45.34%
Apr 16th, 2021 16:00 DELAYED
BID45.57 ASK45.63
Open47.70 Previous Close44.76
Pre-Market- After-Market-
 - -  - -%
Target Price
67.09 
Analyst Rating
Strong Buy 1.22
Potential %
47.22 
Finscreener Ranking
★★★★     53.61
Insiders Trans % 3/6/12 mo.
-100/-100/-94 
Value Ranking
     42.31
Insiders Value % 3/6/12 mo.
-100/-100/-93 
Growth Ranking
★★     45.33
Insiders Shares Cnt. % 3/6/12 mo.
-100/-100/-91 
Income Ranking
 —    -
Market Cap3.66B 
Earnings Rating
Neutral
Price Range Ratio 52W %
60.89 
Earnings Date
5th May 2021

Today's Price Range

44.6147.92

52W Range

25.4958.47

Summary:

Buy

Technical Indicators: Neutral
Moving Averages: Strong Buy
Performance
1 Week
9.65%
1 Month
-0.81%
3 Months
-13.03%
6 Months
30.91%
1 Year
45.34%
3 Years
82.13%
5 Years
-
10 Years
-

TickerPriceChg.Chg.%
APLS45.570.81001.81
AAPL134.16-0.3400-0.25
GOOG2 297.761.10000.05
MSFT260.741.24000.48
XOM56.66-0.3200-0.56
WFC43.841.60003.79
JNJ162.241.85001.15
FB306.18-1.6400-0.53
GE13.39-0.1600-1.18
JPM153.301.13000.74
Financial StrengthValueIndustryS&P 500US Markets
6.80
7.10
0.65
1.85
-10.50
Leverage Ratio 4.20
ProfitabilityValueIndustryS&P 500US Markets
90.00
-79 272.30
-79 204.40
-
-62.96
RevenueValueIndustryS&P 500US Markets
250.65M
3.12
-
-
Earnings HistoryEstimateReportedSurprise %
Q04 2020-0.480.93293.75
Q03 2020-1.53-1.79-16.99
Q02 2020-1.30-1.57-20.77
Q01 2020-1.33-2.29-72.18
Q04 2019-1.15-1.70-47.83
Q03 2019-1.04-1.10-5.77
Q02 2019-0.80-0.98-22.50
Q01 2019-0.72-0.87-20.83
Earnings Per EndEstimateRevision %Trend
3/2021 QR-1.69-14.19Negative
6/2021 QR-1.78-15.58Negative
12/2021 FY-6.480.31Positive
12/2022 FY-5.471.26Positive
Next Report Date5th May 2021
Estimated EPS Next Report-1.69
Estimates Count8
EPS Growth Next 5 Years %42.30
Volume Overview
Volume803.79K
Shares Outstanding80.38M
Trades Count9.91K
Dollar Volume29.62M
Avg. Volume646.55K
Avg. Weekly Volume685.62K
Avg. Monthly Volume724.65K
Avg. Quarterly Volume646.72K

Apellis Pharmaceuticals Inc. (NASDAQ: APLS) stock closed at 45.57 per share at the end of the most recent trading day (a 1.81% change compared to the prior day closing price) with a volume of 808.63K shares and market capitalization of 3.66B. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 374 people. Apellis Pharmaceuticals Inc. CEO is Cedric Francois.

The one-year performance of Apellis Pharmaceuticals Inc. stock is 45.34%, while year-to-date (YTD) performance is -20.33%. APLS stock has a five-year performance of %. Its 52-week range is between 25.49 and 58.47, which gives APLS stock a 52-week price range ratio of 60.89%

Apellis Pharmaceuticals Inc. currently has a PE ratio of -9.10, a price-to-book (PB) ratio of 16.33, a price-to-sale (PS) ratio of 13.34, a price to cashflow ratio of -, a PEG ratio of 2.32, a ROA of -49.82%, a ROC of -134.00% and a ROE of -285.23%. The company’s profit margin is -62.96%, its EBITDA margin is -79 204.40%, and its revenue ttm is $250.65 Million , which makes it $3.12 revenue per share.

Of the last four earnings reports from Apellis Pharmaceuticals Inc., there were 1 positive earnings surprise and 3 negative earnings surprise. The company has EPS estimate of $-1.69 for the next earnings report. Apellis Pharmaceuticals Inc.’s next earnings report date is 05th May 2021.

The consensus rating of Wall Street analysts for Apellis Pharmaceuticals Inc. is Strong Buy (1.22), with a target price of $67.09, which is +47.22% compared to the current price. The earnings rating for Apellis Pharmaceuticals Inc. stock is Neutral (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

Apellis Pharmaceuticals Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.

Apellis Pharmaceuticals Inc. has a Buy technical analysis rating based on Technical Indicators (ADX : 7.89, ATR14 : 2.66, CCI20 : 201.11, Chaikin Money Flow : -0.15, MACD : -0.76, Money Flow Index : 66.69, ROC : 8.37, RSI : 63.57, STOCH (14,3) : 68.20, STOCH RSI : 1.00, UO : 52.17, Williams %R : -31.80), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of Apellis Pharmaceuticals Inc. in the last 12-months were: A. Sinclair Dunlop (Sold 50 000 shares of value $2 631 567 ), Alec Machiels (Option Excercise at a value of $86 775), Alec Machiels (Sold 32 500 shares of value $1 244 700 ), Cedric Francois (Option Excercise at a value of $437 877), Cedric Francois (Sold 40 000 shares of value $1 396 050 ), David Watson (Option Excercise at a value of $432 646), David Watson (Sold 17 433 shares of value $885 473 ), Federico Grossi (Option Excercise at a value of $130 440), Federico Grossi (Sold 21 212 shares of value $894 713 ), Lukas Scheibler (Option Excercise at a value of $199 994), Nicole Perry (Option Excercise at a value of $90 240), Nicole Perry (Sold 24 000 shares of value $1 214 480 ), Pascal Deschatelets (Option Excercise at a value of $16 688), Pascal Deschatelets (Sold 6 250 shares of value $317 125 ), Paul Fonteyne (Buy at a value of $318 068), Victoria L. Brown (Option Excercise at a value of $227 760), Victoria L. Brown (Sold 12 000 shares of value $420 000 )

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
8 (88.89 %)
8 (88.89 %)
6 (75.00 %)
Moderate Buy
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Hold
1 (11.11 %)
1 (11.11 %)
2 (25.00 %)
Moderate Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Strong Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Summary RatingStrong Buy
1.22
Strong Buy
1.22
Strong Buy
1.50

Apellis Pharmaceuticals Inc.

Apellis Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It focused on the development of novel therapeutic compounds to treat disease through the inhibition of the complement system, which is an integral component of the immune system, at the level of C3 the central protein in the complement cascade.

CEO: Cedric Francois

Telephone: +1 617 977-5700

Address: 100 Fifth Avenue, Waltham 02451, MA, US

Number of employees: 374

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

100%0%

Bearish Bullish

58%42%

Bearish Bullish

56%44%

Bearish Bullish

56%44%

News

Stocktwits